← SynDRA
LENRISPODUN
SynDRA canonical compound SYN0038542 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | PDE1A |
|---|
| Mechanism of action | phosphodiesterase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PDE1B INHIBITOR
- PDE4A INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE10A
- PDE8A
- PDE7B
- PDE5A
- PDE4A
- PDE3B
- PDE1B
- PDE11A
- AURKA
- PDE9A
- PDE2A
- ABL1
- MAPK1
- HDAC6
- GSK3B
- FGFR3
- FGFR2
- CSNK1D
- CDK2
- BRPF1
- BRD4
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- ITI-214
- ITI-214 FREE BASE
- IC-200214
- IC200214
- ITI-214F
- ITI214 (FREE BASE)
- PDE1-IN-1
- ITI-002A
- PDE1 inhibitors (oral, cognitive disorders)
- PDE1 inhibitors (oral, cognitive disorders), Takeda
- Dopamine D1 receptor agonist (oral, cognitive disorders), Intra-Cellular Therapies
- ITI-002 series (cognitive disorders), Intra-Cellular Therapies
- PDE1 inhibitors (oral, cognitive disorders), Intra-Cellular Therapies
- ITI-214 free base
- 3GBO34D1BE
- RefChem:150203
- ITI214 free base
- ITI214 (free base)
- ITI-214 (free base)
- Lenrispodun [USAN]
- UNII-3GBO34D1BE
- WHO 11635
- Lenrispodun (USAN)
- ITI214
- PDE4 (R)-(-)-RolipraM
- LENRISPODUN [INN]
- C29H26FN7O
- orb1709390
- SCHEMBL10201342
- SCHEMBL29415040
- GTPL12003
- BBIPVJCGIASXJB-PKTZIBPZSA-N
- BDBM50150119
- MFCD28385866
- AKOS030526280
- compound 3 [PMID: 26789933]
- CS-3621
- DA-74606
- HY-12501
Look up LENRISPODUN in the interactive SynDRA portal →